Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Mallinckrodt
McKesson
Baxter
McKinsey

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

Patent: 7,354,902

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,354,902
Title:Recombinant lactoferrins, methods of production from plants and uses thereof
Abstract: The invention concerns the use of a recombinant nucleotide sequence containing a cDNA coding for a lactoferrin, in particular human lactoferrin, or the derived proteins, and elements enabling a plant cell to produce lactoferrin or the derived proteins, coded by said cDNA, in particular a transcription promoter and terminator identified by the plant cell transcription machinery, to transform plant cells in order to obtain, from these cells, or plants obtained therefrom, lactoferrin or derived proteins.
Inventor(s): Legrand; Dominique (Villeneuve d\'Ascq, FR), Salmon; Valerie (Montville, FR), Spik; Genevieve (Marcq en Baroeul, FR), Gruber; Veronique (Chamalieres, FR), Bournat; Philippe (Clermont-Ferrand, FR), Merot; Bertrand (Volvic, FR)
Assignee: Meristem Therapeutics S.A. (Clermont-Ferrand, FR)
Application Number:10/446,234
Patent Claims:see list of patent claims

Details for Patent 7,354,902

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Meristem Therapeutics S.A. (Clermont-Ferrand, FR) 2017-05-02 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Meristem Therapeutics S.A. (Clermont-Ferrand, FR) 2017-05-02 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Meristem Therapeutics S.A. (Clermont-Ferrand, FR) 2017-05-02 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 7,354,902

Country Patent Number Publication Date
World Intellectual Property Organization (WIPO) 9850543 Nov 12, 1998
United States of America 2003229925 Dec 11, 2003
United States of America 2011092411 Apr 21, 2011
United States of America 6569831 May 27, 2003
United States of America 8334254 Dec 18, 2012
Japan 2001527406 Dec 25, 2001
France 2762850 Feb 11, 2000
>Country >Patent Number >Publication Date

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Dow
McKinsey
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.